Discount Agreement for Doravirin/Lamivudin/Tenofovir
Original notice title
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-32 - Doravirin/Lamivudin/Tenofovir (Wirkstoffkombination)
Opportunity Score
Why this score?
Opportunity
30 / 100
Complexity
20 / 100
Risk factors
No estimated value or volume guarantees; uncertain revenue potential.
Contract terminates automatically on patent/market exclusivity expiry, possibly before end of term.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Nov 2027
- Supply of pharmaceutical product Doravirin/Lamivudin/Tenofovir
- Enter into a discount agreement (Rabattvertrag) with TK
Show full summary
This is an Open House procedure by Techniker Krankenkasse (TK) for concluding discount agreements (Rabattverträge) for the drug combination Doravirin/Lamivudin/Tenofovir. No estimated value is provided. The procedure is open to all eligible pharmaceutical manufacturers meeting specific criteria. Contracts are non-exclusive, with a maximum term of 24 months ending 30 November 2027. Joining is possible at any time during the term. No award criteria apply; any qualifying supplier will be accepted.
Risks
No estimated value or volume guarantees; uncertain revenue potential.
Contract terminates automatically on patent/market exclusivity expiry, possibly before end of term.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical manufacturer (pharmazeutischer Unternehmer) as per §4(18) AMG
- Must have a valid marketing authorization for the drug combination or be authorized to market it
- Must have seat in Germany, another EU member state, or EEA
Requirements may be incomplete.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Discount Agreement for Doravirin/Lamivudin/Tenofovir
Conclusion of discount contracts for the drug combination Doravirin/Lamivudin/Tenofovir under §130c SGB V. Non-exclusive, standardized terms, no negotiations.
Location
Duration
Category
Deadline
Award details
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zur Wirkstoffkombination Doravirin/Lamivudin/Tenofovir zu schließen.
Show original TED data
Original lot title
Open House Originale Rabattverträge 2025-32 - Doravirin/Lamivudin/Tenofovir (Wirkstoffkombination)
Original TED description
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zur Wirkstoffkombination Doravirin/Lamivudin/Tenofovir zu schließen.
Procurement Details
- Publication date
- 12 Oct 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 670890-2025
Documents (1)
Similar tenders
Germany – Site preparation work – VE111 Baustelleneinrichtung (119VM514 / Kronsh,SanDstBw,Ersatzneub. ZInstSanBw)
Poland – Advertising and marketing services – Zaplanowanie i realizacja kampanii Ministerstwa Finansów z zakresu działalności resortu finansów
France – Insurance services – Prestations de services d'assurance pour groupement le groupement hospitalier de territoire Yvelines Nord
Finland – Architectural, construction, engineering and inspection services – Tietomallikoordinaattori-, inventointimittaus- ja mallinnuspalvelujen puitejärjestely 2026-2028 (2028-2030)
Greece – Cultural event organisation services – ΛΕΙΤΟΥΡΓΙΑ ΤΟΥ ΘΕΑΤΡΟΥ ΟΛΥΜΠΙΑ ΜΑΡΙΑ ΚΑΛΛΑΣ ΜΕ ΕΞΕΙΔΙΚΕΥΜΕΝΟ ΠΡΟΣΩΠΙΚΟ
Spain – Architectural, construction, engineering and inspection services – Redacción del Proyecto Básico y de Ejecución, Redacción del Estudio de Seguridad y Salud y Dirección de Obra para la construcción del I.E.S. Nº 1 de 12+0 uds. (Fase 1) en la urbanización El Bosque de Pioz (Guadalajara).
Opportunity Score
Why this score?
Opportunity
30 / 100
Complexity
20 / 100
Risk factors
No estimated value or volume guarantees; uncertain revenue potential.
Contract terminates automatically on patent/market exclusivity expiry, possibly before end of term.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications